hematology - myeloid gene panels

Lab	Test name	Contact	Comments
UZ Leuven MolPLUZ	hematology - myeloid gene panels	Jolien De Bie	Sample type: blood / bone marrow (EDTA, 2-5 ml) Frequency: 1x/week Test type: targeted capture NGS workflow with custom IDT xGen® Lockdown® Probes on an Illumina sequencing instrument Genes: ANKRD26, ASXL1, BCOR, BCORL1, BRAF, CALR, CBL, CEBPA, CSF3R, DDX41, DIS3, DNMT3A, ELANE, ETNK1, ETV6, EZH2, FLT3, GATA1, GATA2, GFI1, HRAS, IDH1, IDH2, JAK1, JAK2, JAK3, KIT, KMT2A, KRAS, MPL, NPM1, NRAS, PDGFRA, PHF6, PPM1D, PTEN, PTPN11, RAD21, RUNX1, SAMD9, SAMD9L, SETBP1, SF3B1, SMC1A, SMC3, SRP72, SRSF2, STAG1, STAG2, TET2, TP53, U2AF1, WAS, WT1, ZRSR2 BELAC accreditation number 215-MED Accredited:
UZA Mol. Diagn.	hematology - myeloid gene panels	K. Vermeulen, M. Le Mercier, M-B Maes	34 genes Haloplex HS NGS panel on MiSeq to screen clinically relevant genes in myeloid malignancies (incl. AML, MDS, CMML, MPN, MDS/MPN). Genes: ANKRD26, ASXL1, BCOR, CALR, CBL, CEBPA, CSF3R, DDX41, DNMT3A, ETNK1, ETV6, EZH2, FLT3, GATA2, IDH1, IDH2, JAK2, KIT, KMT2A, KRAS, MPL, NF1, NPM1, NRAS, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2. Sample Type: Blood, Bone marrow, FFPE samples BELAC accreditation number 204-MED Version date: 09/09/2022 Accredited:
UZ Gent	hematology - myeloid gene panels	Karl Vandepoele, Annelynn Wallaert Joni Van Der Meulen, Barbara Denys	In-house developed, capture-based (HyperCap) 116 gene panel to screen clinically relevant genes in myeloid and lymphoid disorders by NGS: ANKRD26, ARID1A, ASXL1, ATM, B2M, BCL2, BCOR, BCORL1, BIRC3, BRAF, BTG1, BTK, CALR, CARD11, CBL, CBLB, CCL22, CCND1, CD28, CD33, CD58, CD79A, CD79B, CDKN2A, CEBPA, CREBBP, CSF3R, CUX1, CXCR4, DDX41, DDX3X, DIS3, DNMT3A, EGR2, EP300, ETNK1, ETV6, EZH2, FAS, FBXW7, FLT3, FOXO1, GATA1, GATA2, GNA13, GNB1, HAVCR2, HRAS, ID3, IDH1, IDH2, IL7R, IRF4, JAK1, JAK2, JAK3, KIT, KLF2, KMT2A, KMT2D, KRAS, MAP2K1, MEF2B, MPL, MYD88, NF1, NFE2, NFKBIE, NPM1, NOTCH1, NOTCH2, NRAS, NSD2, NUDT15, PHF6, PIK3CA, PIM1, PLCG1, PLCG2, POT1, PPM1D, PRKCB, PRPF8, PTEN, PTPN11, RAD21, RHOA, RUNX1, SBDS, SETBP1, SF3B1, SGK1, SH2B3, SMC1A, SMC3, SOCS1, SRSF2, STAG2, STAT3, STAT5B, STAT6, TCF3, TET2, TNFAIP3, TNFRSF14, TP53, TPMT, TRAF2, U2AF1, UBA1, UBTF, XPO1, WT1, ZEB2, ZRSR2 1x/week BELAC accreditation number 087-MED The same gene panel is also used for certain lymphoid malignancies. Version date: 31/05/2023 Accredited:
UZ Gent	hematology - myeloid gene panels	Karl Vandepoele, Joni Van Der Meulen, Barbara Denys	In-house developed NGS panel to screen the driver genes in presumed polycythemia vera (PV), essential thrombocytosis (ET) or primary myelofibrosis (PMF): CALR, JAK2, MPL 1x/week BELAC accreditation number 087-MED For a more extensive analysis of ET or PMF: see the NGS 68 gene panel Version date: 16/03/2021 Accredited:
CHU Liège - Hemato	hematology - myeloid gene panels	Dr Frédéric LAMBERT	NGS targeted sequencing after hybridization capture, Home brew assay or Sophia Myeloid Solution (MYS) Targets: SH2B3 (LNK); CBL; ASXL1; CALR; CSF1R; CSF3R; DNMT3A; EPOR; ETNK1; EZH2; JAK1; JAK2; JAK3; KIT; MPL; NF1; PHD2; SETBP1; SRSF2; STAT5B; TET2; U2AF35; VHL; ZRSR2; BCROR; BCORL1 Full genes list available upon request. Indications: - MDS diagnosis if >= 1 lineage with > 10% of dysplasia BUT not all WHO criteria met; persistent, unexplained (pan)-cytopenia (>3-6 months) - AML diagnosis & prognostication; - Triple-negative MPNs; - CMML & others "Overlap syndromes" diagnosis; - Atypical/Phi-negative MPNs; BELAC accreditation number: 128-MED Accredited:
CHU Liège - Hemato	hematology - myeloid gene panels	Dr Frédéric LAMBERT & Rafael Carazo	33 Nomenclature Familial MDS/AML syndromes; Inheritred bone marrow failure syndromes (IBMFS): Familial platelet disorder with propensy to myeloid malignancies (RUNX1); Thrombocytopenia 2 (ANKRD26); Familial AML with CEBPA; Familial AML with DDX41; Thrombocythopenia 5 (ETV6); Familial MDS/AML with mutated GATA2; Telomere syndromes (DC); Familial aplastic anemia with SRP72 mutation; Li-Fraumeni syndrome (Therapy related disorders) Inherited predisposition to ataxia, pancytopenia and myeloid malignancies due to SAMD9 or SAMD9L germline mutation (Ataxia pancytopenia syndrome) NGS targeted sequencing after hybridization capture, Home brew assay. Confirmation of germinal status request skin biopsy or fibroblasts'DNA. INFORMED CONSENT REQUESTED BEFORE TESTING: http://www.chu.ulg.ac.be/jcms/c_10919499/formulaire-de-consentement-ngs Accredited:
AZ St-Jan Brugge - Laboratoriumgeneeskunde	hematology - myeloid gene panels	Helena Devos/Friedel Nollet	Qiagen GeneRead custom panel. Genes : ASXL1; CALR; CSF3R; DNMT3A; FLT3; IDH1; IDH2; JAK2; KIT; MPL; NPM1; RUNX1; SETBP1; SF3B1; SRSF2; TET2; TP53; U2AF1; WT1. Version date: 12/09/2017 Accredited:
Jessa Hospital	hematology - myeloid gene panels	Dr. Brigitte Maes, Guy Froyen	AmpliSeq Myeloid panel (Illumina) (DNA + RNA) Genes: ABL1, ASXL1, ATRX, BCOR, BCORL1, BRAF, CALR, CBL, CBLB, CBLC, CDKN2A, CEBPA, CSF3R, CUX1, DNMT3A, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GNAS, HRAS, IDH1, IDH2, IKZF1, JAK2, JAK3, KDM6A, KIT, KRAS, KMT2A, MPL, MYD88, NOTCH1, NPM1, NRAS, PDGFRA, PHF6, PTEN, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SMC1A, SMC3, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2 2x/week on MiSeq Accredited 275-MED Version date: 03/08/2021 Accredited:
AZ Delta	hematology - myeloid gene panels	Geert Martens, Elke Boone	Sample type: blood / bone marrow (300µl - 1 ml) Frequency: 1x/month Test type: TruSight Myeloid (Illumina), NGS Genes: ABL1, ASXL1, ATRX, BCOR, BCORL1, BRAF, CALR, CBL, CBLB, CBLC, CDKN2A, CEBPA, CSF3R, CUX1, DNMT3A, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GNAS, HRAS, IDH1, IDH2, IKZF1, JAK2, JAK3, KDM6A, KIT, KRAS, KMT2A, MPL, MYD88, NOTCH1, NPM1, NRAS, PDGFRA, PHF6, PTEN, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SMC1A, SMC3, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2 Version date: 05/12/2017 Accredited:
UZ Brussel - Molecular Pathology	hematology - myeloid gene panels	Freya Vaeyens	NGS targeted sequencing after hybridization capture, home brew STHT assay (solid and hematological tumors) Genes list available at http://www.brightcore.be/stht Sample Type: blood/ bone marrow Frequency: 1x/week Accreditation: BELAC 141-MED Version date: 10/10/2019 Accredited:
LHUB-ULB	hematology - myeloid gene panels	Pierre Heimann/Laurent Dewispelaere/Pascale Cochaux/Hakim El Housni	TRANSPORT: room temperature, within 24h after sampling FREQUENCY: 1x/week; max TAT: 4 weeks TEST TYPE: In-house developed gene panel using the Qiaseq Targeted DNA custom Panels platform (Qiagen) to screen clinically relevant genes in myeloid disorders: ASXL1, CALR, CSF3R, DNMT3A, ETNK1, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MPL, NPM1, NRAS, PHF6, PLCG2, RHOA, RUNX1, SETBP1, SF3B1, SRSF2, TET2, TP53,U2AF1, WT1 BELAC accreditation number 650-MED The same gene panel is also used in certain T-cell lymphoid malignancies such as AITL Version date: 04/10/2021 Accredited:
LHUB-ULB	hematology - myeloid gene panels	Pierre Heimann/Laurent Dewispelaere/Pascale Cochaux/Hakim El Housni	TRANSPORT: room temperature, within 24h after sampling FREQUENCY: 1x/week; max TAT: 4 weeks TEST TYPE:In-house developed gene panel using the Qiaseq Targeted DNA custom Panels platform (Qiagen) to screen for driver variants in presumed polycythemia vera and essential thrombocytosis: CALR, CSF3R, ETNK1, IDH1, IDH2, JAK2, KRAS, MPL, NRAS, SETBP1, SF3B1, SRSF2, TP53, U2AF1 1x/week BELAC accreditation number 650-MED Version date: 04/10/2021 Accredited:
IPG Gosselies	hematology - myeloid gene panels	P. Vannuffel C. De Rop	Archer VariantPlex Core myeloid panel for the detection of mutations and delins in the following genes: ASXL1, CALR, CEBPA, CSF3R, DNMT3A, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, MPL, NPM1, RUNX1, TET2, TP53, WT1, SETBP1, SF3B1, SRSF2 and U2AF1. NGS Archer - Illumina. Sample type: Blood and bone marrow. BELAC accreditation number: 381-MED. Version date: 07/09/2022 Accredited: